> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-72/
- Published: 2022-04-24T12:00:00.000Z
- Updated: 2026-09-14T17:41:54.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138245

Baton Rouge-based **OncBioMune Pharmaceuticals** is acquiring a generic drug, norepinefrine, that treats low blood pressure and heart failure from **Teva Pharmaceuticals** Industries. OncBioMune says it is acquiring the intellectual property rights and sanitary certificates — which confirms that the drug has been inspected and meets sanitary requirements — for norepinefrine to be marketed in Mexico.

Canada-based **Taro Pharmaceuticals** has entered into an agreement to acquire **Thallion Pharmaceuticals**. The transaction would give Taro rights for development of orphan drug candidate Shigamab, which targets *E.Coli*\-induced hemolytic uremic syndrome that leads to kidney failure.

**GE Healthcare** has acquired wireless fetal monitoring company **Monica Healthcare**. The transaction gives GE rights to Novii, a wearable patch that monitors maternal heart rate, fetal heart rate and uterine activity to the portfolio of its maternal-infant care unit.